HIGHLIGHTS
Mammary gland stromal fibroblasts are mechanically adapted to a soft environment Loss of SHARPIN reduces cell spreading and force generation on soft collagen Low integrin a11b1 level in SHARPIN-null cells causes faster unbinding from collagen Molecular clutch model predicts the lower forces based on faster integrin unbinding
INTRODUCTION
Fibroblasts exert high forces that are implicated in the morphogenetic rearrangement of extracellular matrices (ECMs) (Harris et al., 1981) . In the developing mammary gland, stromal cell-mediated organization of the ECM regulates mammary ductal morphogenesis (Brownfield et al., 2013; Ingman et al., 2006) . Despite this important function, investigations into mammary stromal components are secondary to that of the mammary epithelium. In addition to ECM organization in normal tissue, mammary gland stromal fibroblasts (MSFs) play a central role in the pro-invasive stiffening of breast tumor stroma (Navab et al., 2016) , and therefore, understanding the mechanical aspects of these cells is of clinical interest. Although the role of integrins as cell mechanosensors and transducers is well established, the link between the regulation of integrin activity and the mechanosensing response on different ECM ligands remains poorly understood. SHARPIN is a cytosolic adaptor protein that, among other functions, binds to the intracellular integrin alpha tails and inhibits integrin activity in different cell types in vitro and in vivo (Kasirer-Friede et al., 2019; Peuhu et al., 2017a Peuhu et al., , 2017b Pouwels et al., 2013; Rantala et al., 2011) . We have previously demonstrated that stromal SHARPIN deficiency interferes with normal mouse mammary gland development and collagen fiber assembly in vivo (Peuhu et al., 2017a) . However, how SHARPIN mediates integrin-dependent mechanotransduction remains unresolved.
Collagen is abundant in the mammary gland stroma and plays a key role in regulating the physical and biochemical properties of the mammary gland. Alignment of stromal collagen bundles is critical for normal mammary gland development providing migration cues to the outgrowing duct during puberty (Brownfield et al., 2013; Ingman et al., 2006) . There are four collagen-binding integrin heterodimers in mammals: the more ubiquitously expressed a1b1, a2b1, and a11b1 and the cartilage-specific a10b1 (Zeltz and Gullberg, 2016) . Of these, the fibrillar collagen-binding integrins a2b1 and a11b1 have been strongly linked to collagen remodeling and turnover (Abair et al., 2008; Ivaska et al., 1999; Popova et al., 2007; Riikonen et al., 1995; Tiger et al., 2001) and a11b1 to the induction of cancer stromal stiffness (Navab et al., 2016; Zeltz et al., 2019) . Furthermore, ''trail blazer'' breast cancer cells with high invasive capacity are characterized by high integrin a11b1 expression (Westcott et al., 2015) . Nevertheless, integrin a11b1 functions are rather poorly understood, and the role of this receptor in regulating cell-collagen interactions in the mammary gland has not been previously studied.
In order to sense the properties of the surrounding ECM, cells use dynamic molecular bonds, often referred to as molecular clutches, to exert forces within the cell boundary (Elosegui-Artola et al., 2018) . A molecular clutch can be defined as a dynamic link between the ECM, integrin adhesion receptors, intracellular adaptor proteins, and the actomyosin cytoskeleton . By quantification of the molecular clutch binding dynamics, and using mathematical modeling, one can predict the average force transmission of cells to the ECM as a function of substrate stiffness .
Here, we have combined mathematical modeling with cell biology to investigate the biomechanical properties of primary mouse MSFs and to understand how the integrin inhibitor SHARPIN affects integrindependent force generation and mechanotransduction. We find that, somewhat counterintuitively, in spite of having higher integrin b1 activity SHARPIN-deficient MSFs were defective in spreading on soft hydrogels with a stiffness similar to the mammary gland tissue in vivo. They also had faster force-induced cell-ECM unbinding rates. Interestingly, both of these defects were specific to collagen and not observed on fibronectin. The molecular clutch model predicted that increased clutch unbinding rates result in the loss of stiffness-dependent traction maximum and increased actin flow rates at low rigidities. Importantly, these predictions were recapitulated experimentally in SHARPIN-deficient primary MSFs on collagen I. SHAR-PIN-deficient MSFs had significantly downregulated collagen-binding integrin a11b1 levels, explaining mechanistically their unexpected inability to couple to collagen. These data highlight an important divergence in the regulation of collagen I-and fibronectin-binding integrin heterodimers in the mammary gland stroma with implications for the mechanical response of fibroblasts. Moreover, these insights are likely to improve our understanding of fibrotic diseases including cancer where fibroblasts exhibit deregulated integrin activity (Erdogan et al., 2017; Glentis et al., 2017) .
RESULTS

Increased Integrin Activity Correlates with Reduced Spreading of Mouse Mammary Gland Fibroblasts on Soft Collagen I, but Not on Soft Fibronectin, -Coated Matrices
Based on previous observations that primary MSFs from SHARPIN-deficient mice (chronic proliferative dermatitis null mutation, cpdm; Sharpin cpdm/cpdm ; Sharpin cpdm ) (HogenEsch et al., 1993; have increased integrin b1 activity but, counterintuitively, impaired capacity to contract collagen gels (Peuhu et al., 2017a) , we sought to investigate the link between integrin activity and force transduction. We first confirmed by flow cytometry the cell-surface levels of total and active integrin b1 with conformation-specific antibodies. As expected, Sharpin cpdm MSFs expressed lower total integrin b1 cell-surface levels but equal levels of active integrin b1 compared with SHARPIN-expressing (Sharpin +/+ or Sharpin cpdm/+ ; from here on referred to as wild-type) cells, indicating that in Sharpin cpdm MSFs a higher proportion of integrin b1 is in the active conformation on the cell surface ( Figures 1A and S1A ), in line with our previous studies with MSFs (Peuhu et al., 2017a) and other cell types (Peuhu et al., 2017b; Rantala et al., 2011) . Next, we studied the ability of wild-type and Sharpin cpdm MSFs to spread in response to ECM stiffness and ligand type. MSFs were seeded at equal density on soft (2 kPa) fibronectin or collagen I (a saturating concentration of 20 mg/mL of each ligand was used, Figure S1B ) pre-coated polyacrylamide gels, approximating the stiffness of the mammary tissue in vivo (Lopez et al., 2011; Peuhu et al., 2017a; Plodinec et al., 2012) . As expected based on the higher integrin b1 activity and faster focal adhesion (FA) turnover compared with wild-type MSFs (Peuhu et al., 2017a; Rantala et al., 2011) , Sharpin cpdm MSFs spread more compared with wild-type MSFs when seeded on fibronectin-coated hydrogels ( Figures 1B and1C) . In contrast, on 2 kPa collagen-I-coated hydrogels Sharpin cpdm MSFs were less spread than wild-type MSFs ( Figures 1B and1C) . When cell spreading area was measured on a stiffness range from 0.8 to 13 kPa (Figure 1C) , on collagen-I-coated hydrogels, wild-type MSFs displayed a spreading optimum on 2 kPa, whereas Sharpin cpdm MSFs were significantly smaller and only fully spread at 13 kPa ( Figure 1C ). These data present an unexpected conundrum; at lower stiffness [corresponding to the higher end of the rigidity spectrum reported for mammary gland tissue in vivo, 0.1-2 kPa (Peuhu et al., 2017a; Plodinec et al., 2012) ], loss of SHAR-PIN (coinciding with increased integrin b1 activity) correlates with defective MSF spreading on collagen I, whereas on fibronectin the opposite is observed.
Given that Sharpin cpdm MSFs have faster FA dynamics (increased assembly and disassembly rates) on collagen-coated rigid glass substrate (Peuhu et al., 2017a) , we next evaluated the effect of SHARPIN deficiency on FA maturation (number and average length) on a range of hydrogel rigidities. Vinculin, a mechanosensitive adaptor molecule recruited to mature FA (Chen et al., 2006; del Rio et al., 2009) , was immunolabeled in wild-type and Sharpin cpdm MSFs plated on 0.8-13 kPa collagen-I-coated hydrogels (Figures 1D and S1C). Wild-type and Sharpin cpdm MSFs ( Figure 1D ) demonstrated similar FA number and length on collagen-I-coated hydrogels (Figures 1E and 1F) . Interestingly, both wild-type and Sharpin cpdm primary MSFs formed mature, vinculin-containing adhesions on soft matrices reaching the maturation maxima already on 2-4 kPa ( Figure 1F ). On fibronectin, Sharpin cpdm MSFs demonstrated either longer or more FA on 2-4 kPa hydrogels (Figures S1D-S1F), consistent with increased cell spreading (Figures 1B and1C) . Furthermore, MSFs exhibited nuclear localization of the mechanosensitive transcription factor Yes-associated protein (YAP) at 2 kPa stiffness ( Figure S1G ). This localization was reduced in Sharpin cpdm MSFs ( Figure S1G , H). The nuclear localization of YAP and the ability of MSFs to generate elongated, stress-fiber-linked adhesions on a low stiffness are counter to the stiffness-induced adhesion reinforcement/maturation and nuclear YAP translocation detected in other cell types , possibly mirroring the adaption of these primary cells to their soft growth environment in the mammary gland (Lopez et al., 2011; Peuhu et al., 2017a; Plodinec et al., 2012) . In conclusion, Sharpin cpdm MSFs demonstrate reduced capacity to spread on soft collagen I-coated matrices, whereas the opposite occurs on fibronectin-coated substratum.
Increased Integrin Activity Correlates with Faster Integrin-Collagen Binding Dynamics in MSFs
We then assessed how the altered integrin activity in Sharpin cpdm MSFs affects the binding and unbinding properties of the cells to matrix ligands (Figure 2A 30 min vs. 20-35 min; (Gonzá lez-Tarragó et al., 2017; Jones et al., 2015) ] and recruit the same core-adhesome proteins as the adhesions that form on the basal side of adherent cells (Guilluy et al., 2011; Jones et al., 2015) . Sharpin cpdm MSFs displayed slightly increased recruitment of integrin b1 to collagen-I-coated silica beads when compared with wild-type cells, whereas no significant differences in binding to fibronectin-coated beads were observed ( Figure 2B ). We then employed a magnetic tweezers setup (Elosegui-Artola et al., 2014), a method that allows quantitative measurement of the strength of receptor-ligand bonds, to apply force to collagen I or fibronectin-coated beads attached to cells, and evaluated the time required to detach beads from cells (Figure 2A ). Detachment times of collagen-coated beads were significantly lower for Sharpin cpdm MSFs compared with wild-type cells ( Figure 2C ). However, no significant differences were observed with fibronectin-coated beads ( Figure 2C ). The significant decrease in bead detachment time under force suggests that unbinding rates under force are increased. Thus, overall the results are consistent with an effect of SHARPIN deficiency in increasing both binding and unbinding rates of integrins to collagen, thereby maintaining the overall recruitment constant.
Molecular Clutch Model Predicts the Absence of Traction Peak in Sharpin cpdm Cells at Biologically Relevant Rigidities
The ability of cells to sense and respond to rigidity, and apply force to the matrix, is regulated by the different components of the adhesive and contractile molecular machinery that functions jointly as a cellular molecular clutch (Case and Waterman, 2015; . Clutch dynamics are a function of several parameters: the number and binding dynamics of integrin-ECM bonds, reinforcement of the integrin-actin link through talin unfolding and vinculin recruitment, actomyosin contractility, and substrate compliance. Unlike previously studied cell types , the MSFs are able to generate fully mature adhesions at low stiffness. This suggests that MSFs should exhibit the fundamental prediction of the molecular clutch, a biphasic force/rigidity relationship, which is almost always masked by the fact that adhesion growth and reinforcement normally occur only at high rigidities . This exciting scenario prompted us to measure the remaining necessary parameters required for computational modeling of the molecular clutch in these cells. Actomyosin contractility is an important component of the molecular clutch and is regulated by phosphorylation of myosin light chain 2 (pMLC2). In talin 1À/À knockout mouse embryonic fibroblasts (MEFs) (talin 1 À/À MEFs), which display a wild-type phenotype due to compensatory upregulation of endogenous talin 2 and have previously been studied with comparable methods (Elosegui-Artola et al., 2016), pMLC2 levels are largely independent of substrate stiffness . We compared our MSFs with the talin 1 À/À MEFs and observed increasing pMLC2 levels in MSFs in response to increasing stiffness (Figures 3A, S2A, and S2B), similar to the previously observed response of vascular smooth muscle cells (Polte et al., 2004) . Furthermore, higher pMLC was observed in MSFs plated on soft substrate as compared with talin 1 À/À MEFs (Elosegui-Artola et al., 2016) ( Figure S2A ). However, no significant differences in pMLC2 were detected between wild-type and Sharpin cpdm MSFs, suggesting that myosin activity remains predominantly unaffected in the absence of SHARPIN.
Taking into consideration these experimentally determined MSF features, we employed the computational model of the molecular clutch . It predicts that in the absence of changes in integrin recruitment or adhesion growth as a function of stiffness, the cells should display a biphasic force/rigidity response, even if myosin contractility increases with rigidity ( Figure 3B ). The other prediction arising from our modeling is that increased integrin binding and unbinding rates, as observed in Sharpin cpdm MSFs, should displace the traction force peak to higher rigidities. To test the model predictions, we measured cell-matrix force transmission using traction force microscopy. As predicted, wild-type cells Figure S2 and Table S1. iScience 23, 100907, March 27, 2020 on collagen I displayed a biphasic response of force as a function of stiffness, on the lower stiffness range, with a force maximum at 2 kPa ( Figure 3C andS2C ). Thus, MSFs represent the first mammalian primary cell type that shows this predicted biphasic force response without genetic perturbation. In Sharpin cpdm cells, the concomitant increase in binding and unbinding rates should shift the force curve, displacing the force peak to higher rigidities. Accordingly, the maximum force peak at 2 kPa was absent ( Figures 3C and S2C) , closely replicating the result of the molecular clutch modeling ( Figure 3B ). In this case, no force peak was observed, potentially because it was displaced to a stiffness above the range where traction forces were measured experimentally. Of note, wild-type cells exhibit a stiffness-dependent additional increase in force transmission above 4 kPa that is not predicted by the model indicating that the modeling corresponds to the experimental data only in the lower stiffness range. The nature of this regime remains unknown and warrants further investigation.
Finally, the molecular clutch model also predicts that changes in force should inversely correlate with actin flow. As predicted, actin flow of actively spreading (plated for 45-105 min) Sharpin cpdm cells (average 51 nm/s) on 2 kPa collagen-I-coated hydrogels was also elevated with respect to wild-type cells (average 35 nm/s) ( Figures 3E and3F) . Because of the limited transfection efficiency in the primary MSFs and the need to isolate them freshly from mouse mammary gland, this single stiffness was selected based on the highest differences in traction force measurements. Interestingly, in stably adhered MSFs (plated for 4 h) on 2 kPa collagen-I-coated hydrogels, very slow actin retrograde flow was observed compared to talin 1 À/À MEFs ( Figure S2D ), and measurement of actin flow in MSFs was beyond the detection limit. This is in stark contrast to the rapid actin flow detected in other cell types on soft substrate (Bangasser et al., 2017; , further demonstrating the adaption of MSFs to a soft environment. This may be attributed, in part, to integrin expression. We compared the cell-surface levels of several integrin subunits in talin 1 À/À MEFs and wild-type MSFs and observed that MSFs express nearly two times more integrin b1 and markedly more integrin a1-and a11-subunits compared to talin 1 À/À MEFs (Figure S2E ) that spread poorly on soft collagen ( Figure S2F ).
Consistent with the fact that no differences in adhesion behavior under force were observed with fibronectincoated beads ( Figure 2C ), wild-type and Sharpin cpdm cells exerted the same forces on fibronectin-coated substrates irrespective of stiffness and the cells displayed monotonic increase in force with increasing rigidity (Figure 3D) . In contrast to collagen I substrate, MSFs did not show a force maximum at low rigidities on fibronectin. As in Sharpin cpdm cells on collagen, this lack of a biphasic force response could result from the limited stiffness range used in these experiments (0.6-14.5 kPa) and suggests that the force maximum for MSF on fibronectin is exerted at a stiffness above 14.5 kPa. Our observations support the view that different integrin heterodimers form integrin-ligand bonds with different strengths depending also on ECM composition, which leads to variations in the force maximum on different ECM ligands.
Together, these data demonstrate that SHARPIN deficiency, and the consequent increase in integrincollagen unbinding rate, lead to significant effects in mechanotransduction in MSFs, providing a possible explanation to our previous finding that Sharpin cpdm MSFs are unable to remodel collagen in vitro and are defective in supporting generation of mammary gland stromal architecture supportive of normal development and ductal outgrowth (Peuhu et al., 2017a) .
Integrin a11b1 Protein Levels Regulate the Spreading of MSFs on Soft Matrices
Next, we asked how loss of SHARPIN could affect integrin binding dynamics and what the consequent effects are. One potential explanation is that Sharpin cpdm and wild-type MSFs exhibit differences in collagen-binding integrin expression, leading to different ECM binding properties. An RNA sequencing dataset of wild-type and Sharpin cpdm MSFs (Peuhu et al., 2017a) was analyzed for all the matrix-binding integrin subtypes ( Figure S3A ). Of the collagen-binding integrin alpha subunits (Itga1, Itga2, Itga10, Itga11), which all form a heterodimer with the integrin b1 subunit, Itga11 was the predominant a-subunit expressed at mRNA level, Itga1 was detected at low levels and Itga10 or Itga2 were not detected. Importantly, no significant differences in integrin mRNA expression levels were observed between wild-type and Sharpin cpdm MSFs ( Figure S3A ).
Next we analyz Pa collagen-I-coated hydrogels directly after isolation from the mouse mammary gland ( Figure S3B) , indicating that the observed difference in integrin a11 is not induced by in vitro culture on stiff fibronectin-rich substratum (plastic in the presence of serum fibronectin) and is prominent under conditions when collagen I is the only provided ligand ( Figure S3C) .
As inactive and active integrins are trafficked and degraded differently (Arjonen et al., 2012; Rainero et al., 2015) , we speculated that the increased relative activity of integrin b1 could lead to increased targeting of integrin a11b1 to lysosomal degradation in Sharpin cpdm MSFs. This hypothesis was supported by the fact that SHARPIN-deficient MSFs displayed more integrin a11 co-localization with Lamp1 (lysosomal marker) than wild-type MSFs (Figures 4G and 4H) . Furthermore, we observed accumulation of integrin a11 to the Lamp1-positive compartment when MSFs were treated with the lysosomal degradation disruptor Bafilomycin A1 (Figures 4G and 4H) . These data suggest that a subset of integrin a11 traffics to lysosomal degradation in MSFs and that this is enhanced in SHARPIN-deficient cells.
To investigate whether the reduced surface expression of integrin a1 and a11 in Sharpin cpdm MSFs could be responsible for the impaired capability to spread on a compliant collagen-I-coated surface, we analyzed cell spreading following siRNA-mediated downregulation of integrin a1 or integrin a11 ( Figure 5A ), confirmed by qPCR ( Figure S3D ). In wild-type MSFs downregulation of integrin a11, but not integrin a1, led to significantly reduced cell spreading on 2 kPa collagen-I-coated hydrogels that resembled the phenotype of Sharpin cpdm MSFs ( Figure 1B) . In contrast, no significant differences in cell area were observed when the endogenously lower integrin a1 and integrin a11 levels were silenced in Sharpin cpdm MSFs ( Figure 5A ). These data indicate that appropriate levels of integrin a11, but not integrin a1, are important for regulating the spreading of MSFs on soft collagen-I-coated substrates. This could be linked to the fact that integrin a11 mediates strong binding to and contraction of fibrillar collagen I (Tiger et al., 2001) , whereas integrin a1 prefers non-fibrillar collagen IV and has lower binding affinity to fibrillar collagens (types I, II, and III) (Tulla et al., 2001) . However, this remains to be investigated.
To verify that integrin a11 levels are critical for collagen I interaction of MSFs, we performed rescue experiments with ectopically expressed EGFP-tagged human integrin a11. Reintroduction of integrin a11 in Sharpin cpdm MSFs on collagen-I-coated 2 kPa hydrogels reversed their defective spreading ( Figures 5B  and 5C ). In contrast, overexpression of integrin a11-EGFP in wild-type MSFs modestly, albeit, non-significantly decreased cell spreading ( Figures 5B and 5C ). In addition, reintroduction of integrin a11 by ectopic expression partially rescued the ligand detachment time in Sharpin cpdm MSFs ( Figure 5D ). Taken together, these results demonstrate that integrin a11b1 is essential in the integrin-collagen I binding dynamics and spreading of MSFs on soft collagen-I-coated substrates and that the impaired mechanotransduction of SHARPIN-deficient MSFs is coupled to reduced integrin a11b1 protein expression level.
DISCUSSION
Here we have investigated the mechanotransduction of mammary gland stromal fibroblasts to gain insight into the biologically essential role of these cells in sculpting the mammary gland stromal architecture in vivo (Peuhu et al., 2017a) . Taking this experimentally challenging primary cell model (compared with the immortalized cell lines studied previously) has provided two interesting and unexpected observations related to tissue-specific characteristics of mechanotransduction. First, our data comparing wild-type and SHARPINdeficient cells provide a striking example of how, even if major mechanical regulators such as myosin contractility are not affected, merely changing integrin properties under force can dramatically affect the cell's mechanoresponse. Second, the fact that wild-type MSFs exhibit mature, vinculin-associated FA irrespective of matrix stiffness allowed us to decouple traction force generation from adhesion maturation, leading to the fundamental clutch model prediction of a biphasic traction-stiffness relationship that is otherwise very elusive to observe (Elosegui-Artola et al., 2018).
The differential regulation of collagen-and fibronectin-binding integrins and the mechanobiological implications of these differences remain poorly understood. Here, we have investigated the consequences of SHARPIN deficiency on cell mechanosensing, integrin ligand-binding dynamics, and traction force generation and conducted computational modeling of these events. Our data demonstrate that in the absence of the integrin activity regulator SHARPIN, the protein levels of the collagen-binding integrin a11b1 are downregulated. This is likely to be the main reason for the significantly increased unbinding of SHARPIN-deficient MSFs from collagen-coated beads under force. As the remaining integrin a11b1 is more likely to be in the primed active conformation, due to the increase in relative integrin b1 activity, this could account for the small increase of integrin recruitment to collagen. These faster cell-collagen binding dynamics are in line with the previously reported rapid adhesion turnover of SHARPIN-deficient MSFs (Peuhu et al., 2017a) . Importantly, the molecular clutch model was able to predict the absence of traction peak and increased actin flow rate at low rigidities based on increased clutch binding and unbinding rates to collagen, measured by magnetic tweezers in SHARPIN-deficient cells. Of note, whereas the response to force of integrin-collagen bonds is not known, our model assumed a catch bond behavior. This should, however, not affect our conclusions, because the key aspects of the molecular clutch model found here (biphasic behavior, plus the role of fold changes in binding and unbinding rates) are general to both catch and slip bonds (Bangasser et al., 2013) . Our model failed, however, to predict the final increase in force transmission in wild-type cells with increasing stiffness. Although the details of this regime warrants further investigation, we note that in conditions with very low actin flow rates, mature adhesions, and very stable actin fibers, cytoskeletal reorganization events other than fast actin flow could be determinant of the cellular force transmission (Oakes et al., 2012) . In all, we acknowledge that the model prediction corresponds to the experimental data only in the soft stiffness range, possibly because not all cellular parameters have been, and can be, taken into account by the molecular clutch model.
Although SHARPIN regulates the activity of both collagen-and fibronectin-binding integrins (Rantala et al., 2011) , the low levels of fibrillar collagen-binding integrin a11 in SHARPIN-deficient MSFs results in different mechanosensitive responses of these cells on collagen and fibronectin. This is in line with the established role of integrin a11b1 (Lehnert et al., 1999) , in the regulation of collagen contractility Tiger et al., 2001) and in collagen-linked disease conditions, such as fibrosis, cancer invasion, and particularly in cancer-associated fibroblasts (Bansal et al., 2017; Navab et al., 2016) . The regulatory pathways modulating the activity of collagen-binding integrins may be distinct from other integrin heterodimers.
The vast majority of studies investigating integrin activation are based on the platelet-specific integrin aIIbb3 and the fibronectin receptors integrin a5b1 and avb3, which are primarily regulated by inside-out Figure S3 . and outside-in signaling. In turn, only a few studies have addressed activity regulation in the context of collagen-binding integrins. Heterodimerization of a1b1 and a2b1 integrins has been postulated to have a key role in their activity regulation based on the lower affinity of integrin a1 and a2 to integrin b1 (Lu et al., 2016) . Thus, regulation of the expression levels of collagen-binding integrins may be particularly important for their ligand-binding dynamics.
SHARPIN is a multifunctional adapter protein that has been implicated in a number of other signaling pathways, including inhibition of integrin activity (Kasirer-Friede et al., 2019; Peuhu et al., 2017a Peuhu et al., , 2017b Pouwels et al., 2013; Rantala et al., 2011) . SHARPIN promotes canonical Nuclear factor (NF)-kB activation (Gerlach et al., 2011; Tokunaga et al., 2009 ) and other inflammatory signaling cascades as part of the linear ubiquitin assembly complex (LUBAC) (Chattopadhyay et al., 2016; Dubois et al., 2014; Rodgers et al., 2014; Zak et al., 2011) . Furthermore, SHARPIN regulates the functions of the Arp2/3 protein complex (Khan et al., 2017) , T cell receptor , and caspase 1 (Nastase et al., 2016) in an LUBAC-independent manner and interacts with PTEN (He et al., 2010) , SHANK proteins (Lim et al., 2001) , and EYA transcription factors (Landgraf et al., 2010) . In this study, reduced integrin a11 protein levels were directly linked to mechanobiological phenotypes in SHARPIN-deficient MSFs, whereas integrin expression at the transcriptional level remained comparable to wild-type MSFs. Because NF-kB is a transcription factor that functions predominantly through regulation of gene expression, our data imply that NF-kB might not be the primary mechanism involved in the regulation of integrin a11 in SHARPIN-deficient MSFs. Currently, we lack the detailed mechanisms accounting for the reduced integrin a11 protein levels in SHARPIN-deficient MSFs and in wild-type MSFs upon SHARPIN silencing. However, it is likely that increased lysosomal trafficking of integrin a11, in the absence of SHARPIN, is contributing to elevated integrin degradation in these cells. This would be in line with previous studies linking integrin activation to reduced receptor recycling rates and increased lysosomal degradation (De Franceschi et al., 2015) .
Together, our findings demonstrate how altered integrin activity in SHARPIN-deficient primary MSFs correlates with deregulated cell spreading and traction force generation in response to substrate ligand composition and stiffness. The central role for integrin a11, uncovered here, in regulating mechanotransduction on collagen may also be essential to the pathological behavior of fibroblasts in cancerous or fibrotic tissues. As both SHARPIN and integrin a11b1 are significant regulators of cancer tumorigenesis and dissemination, as well as fibroblast contractility and collagen remodeling (He et al., 2010; Navab et al., 2016; Peuhu et al., 2017a; Tamiya et al., 2018; Zhu et al., 2007) , increased understanding of their functional interplay is of wide interest. Finally, our finding that the mechanical output of fibroblasts can be strongly influenced by a single parameter of the molecular clutch, the integrin binding dynamics, highlights the tuneability of mechanotransduction and its ability to trigger specific outputs in response to both internal and external parameters.
Limitations of the Study
Our current results indicate that absence of SHARPIN results in downregulation of integrin a11 protein levels. We find that integrin a11 localizes slightly more in lysosomes in SHARPIN-deficient than wild-type cells. This suggests that altered receptor trafficking and increased degradation may contribute partially to the lower integrin a11 expression. However, additional mechanisms, such as altered mRNA translation, may also be involved. Therefore, more follow-on studies are necessary to fully unravel the mechanism of how SHARPIN regulates integrin a11 levels.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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Animals
The C57BL/KaLawRij-Sharpin cpdm /RijSunJ mouse strain (Stock No: 007599) with a spontaneous chronic proliferative dermatitis (cpdm) mutation in Sharpin gene leading to the complete loss of SHARPIN protein (HogenEsch et al., 1993; was acquired from The Jackson Laboratory (Bar Harbor, ME). The colony was maintained and genotyped as previously described . Six to seven week-old, female Sharpin cpdm (Sharpin cpdm/cdpm ) mice and littermate wild-type mice (Sharpin +/+ or Sharpin +/cpdm ) were used for MSFs isolation. Mice were housed in standard conditions (12-h light/dark cycle) with food and water available ad libitum. The viability, clinical signs and behaviour of the mice were monitored daily. For euthanasia, cervical dislocation was used in conjunction with CO2. All animal experiments were ethically assessed and authorised by the National Animal Experiment Board and in accordance with The Finnish Act on Animal Experimentation (Animal licence number ESAVI-9339-04.10.07-2016)
Isolation of primary cells
Isolation of MSFs was performed as previously described . Briefly, mouse mammary glands were dissected after sacrifice, lymph nodes removed and the tissue moved to ice cold PBS. The tissue was first mechanically disrupted by mincing with scalpel followed by 2-3 h enzymatic digestion (1% L-glutamine, insulin 5 µg/ml, gentamycin 50 µg/ml, 5% FCS and 2 mg/ml collagenase in DMEM/F-12), and DNAse I treatment (20 U/ml). Fibroblasts were isolated by repeated pulse centrifugation (1500 rpm) and collecting each time the supernatant that contained the stromal cells. After the last pulse centrifugation, the collected supernatant was pelleted and resuspended in growth medium (1% Lglutamine, 1% penicillin/streptomycin, 5% FCS in DMEM/F-12) and the cells plated for culture. Medium was replaced the next day to remove non-adherent and dead cells. Throughout the study, cells were grown for a maximum of 5 passages before being discarded and experiments were performed on multiple cell isolations each of which originated from 2-4 animals.
Cell culture
The talin1 -/-MEF cell line was described previously and was cultured in DMEM containing 15 % FCS.
Transient transfection and gene silencing
Plasmids [mEmerald-Lifeact-7 (Addgene, #54148) and hITGA11-GFP (pBJ1 human integrin alpha 11-EGFP; Erusappan, P., et al. Integrin α11 cytoplasmic tail is required for FAK activation to initiate 3D cell invasion and ERK-mediated cell proliferation. Manuscript in preparation)] were transfected using DNA-In reagent (GST-2131, MTI Global Stem) or Lipofectamine 3000 (L3000075, ThermoFisher) according to the manufacturer's instructions. Briefly a transfection mixture of DNA-In reagent and plasmid was prepared in 1:3 ratio (µg DNA: µl DNA:In) in 250 µl Optimem and incubated for 15 min before transfection. The transfection mixture was added to adhered cells grown on a 6-well plate in 2.5 ml fresh media and cells incubated for 24 h. For transfection with Lipofectamine 3000 reagent a mixture of ratio 4:4:2.5 (µl Lipofectamine 3000 reagent: µl P3000TM Enhancer reagent: µg DNA) was prepared in 500 µl Optimem and incubated for 15 minutes before adding to adhered cells grown on a 6-well plate in 2 ml fresh antibiotic free media and cells incubated for 24 h.
ON-TARGETplus
Mouse Itga1 (109700; 5'-CUUUAAUGACGUCGUGAUU-3', 5´-GCCUAUGACUGGAACGGAA-3', 5´-CCACAAUUGACAUCGACAA-3', and5'-AGGGCAAGGUGUACGUGUA-3') and Mouse Itga11 (319480; 5'-AUGGAUGAGAGGCGGUAUA-3´, 5'-UCAGAAGACAGGAGACGUA-3', 5'-GCAUCGAGUGUGUGAACGA-3', and 5'-CCAGCGACCCUGACGACAA-3') siRNA -SMARTpools were ordered from Dharmacon, and SHARPIN siRNA (5′-GCUAGUAAUUAAAGACACAd(TT)-3′) and the scramble Allstars negative control siRNA were ordered from QIAGEN. Gene silencing was performed using siRNA oligonucleotides and Lipofectamine RNAiMax reagent (13778150, Thermo Fisher Scientific) according to the manufacturer's protocol. Briefly a mixture in 4:3 ratio (µl RNAiMax: µl siRNA) was prepared in 200 µl Optimem and incubated for 20 min before adding to adhered cells grown on a 12-well plate in 400 µl fresh media and cells incubated for 48 h.
Preparation of polyacryl-amide hydrogels
35 mm glass bottom dishes with 14 mm bottom wells (Cellvis, catalog number D35-14-1-N) were treated with 1 ml Bind Silane solution (7.14% Plus One Bind Silane (Sigma, GE17-1330-01), 7.14% acetic acid in 96 % ethanol) for 30 min, washed twice with 96 % ethanol and left to dry completely. A hydrogel mixture containing 7.5-18 % acrylamide solution (Sigma, catalog number A4058) and 0.06-0.4 % bis acrylamide solution (Sigma, catalog number M1533), diluted in PBS up to a final volume of 500 µl was prepared to obtain hydrogels ranging in stiffness from 0.75-13 kPa. The polymerization of the mixture was initialized by adding 5 µl 10 % ammonium persulfate (BioRad, catalog number 1610700) and 1 µl N,N,N′,N′-Tetramethylethylenediamine (Sigma, catalog number T9281). The hydrogel solution was quickly vortexed, 11.7 µl was added on top of the glass bottom dish, and a 13 mm glass coverslip carefully placed on top of the drop and the gel was let to polymerize for 1 h RT incubation. After polymerization, the coverslip was carefully removed and the gel incubated with PBS to prevent drying. The stiffness of the hydrogels was confirmed by atomic force microscopy as previously described (Närvä et al., 2017) .
Gel surface activation and coating
Gels were incubated for 30 min on slow agitation with 500 µl Sulfo-SANPAH activation solution [0.2 mg/ml Sulfo-SANPAH (Sigma, catalog number 803332), 2 mg/ml N-(3-Dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride (Sigma, catalog number 03450) in 50 mM Hepes] followed by 10 min UV-light activation. After the activation gels were washed three times with PBS and coated with either fibronectin (Merck-Millipore, catalog number 341631) (20 µg/ml) or collagen type I (Merck-Millipore, catalog number 08-115) (20 μg/ml).
Analysis of ECM ligand coating saturation
To determine the saturating concentration of the ECM coating, we analysed collagen I and fibronectin density on Sulfo-SANPAH -activated 2 kPa hydrogels coated with fibronectin or collagen I at a range of concentrations (0.1-50 µg/ml). Activated and coated gels were blocked with 5 % bovine serum albumin (Sigma, catalog number A3294) and then incubated with the primary antibodies anti-fibronectin (Sigma, catalog number F3648) or anti-Collagen I (Novus Biologicals, catalog number NB600-408) followed by incubation with the secondary antibody Alexa fluor 568 anti-rabbit (Thermo Fisher, catalog number A10042). Intensity of the antibody staining was imaged by confocal microscopy, and the relative fluorescence intensity was calculated after the subtraction of background fluorescence from non-ligand coated samples.
Immunofluorescence
Cells were fixed and permeabilized with 0.1 % Triton X-100 in 4 % PFA for 8 minutes followed by 10 min fixation with 4 % PFA. When Bafilomycin A1 was used, cells were treated with 100 nM Bafilomycin A1 (Merck-Millipore, catalog number 196000) solubilized in DMSO for 6h prior to fixation. For antibody staining against integrin α11 samples were fixed with methanol for 10 min -20 ℃, followed by 10 min 0.1 % Triton X-100 permeabilization in RT. To block unspecific binding of antibodies cells were incubated in 10 % horse serum (HRS) for 1 h in RT. Primary and secondary antibodies were diluted in 10 % HRS and incubated for 1h in RT. Primary antibodies used: mouse (ms) anti-vinculin (V9131, Sigma-Aldrich, 1:500), rat anti-LAMP1 ([1D4B], ab25245, Abcam, 1:100), ms anti-YAP (sc-101199, Santa Cruz, 1:100), rabbit (rbt) anti-mouse integrin α11 (provided by Donald Gullberg, 1:200) and rat anti-integrin β1, clone MB1.2 (LV1766450, Millipore, 1:100). Secondary antibodies used: Alexa Fluor 488 anti-mouse (A-21202, Thermo Fisher, 1:400), Alexa Fluor 488 anti-rabbit (A-21206, Thermo Fisher, 1:400), Alexa Fluor 647 anti-rat (A-21247, Thermo Fisher 1:400) and Alexa Fluor 594 anti-rat (A21209, Thermo Fisher 1:400). F-actin was stained with Phalloidin-Atto 647N (65906, Sigma, 1:400), incubated together with secondary antibodies and nuclei with DAPI (D1306, Life Technologies 1:3000) for 10 min RT after secondary antibody incubation.
Quantification of immunofluorescence imaging
Quantification of the cell area and the number, average size, and average length (Feret diameter i.e. the longest distance between any two points along the object boundary, also known as maximum caliper) of adhesions per cell was based on vinculin immunofluorescence labeling. Quantification of the nuclear:cytoplasmic ratio of YAP was performed with CellProfiler from maximum intensity projection (MIP) images. Nuclei were segmented based on the DAPI staining, mean intensity was quantified for the nuclei and the surrounding cytoplasms. Quantification of the co-localization of integrin α11 and Lamp1 was performed with the ImageJ plugin ComDet, https://github.com/ekatrukha/ComDet (Fréal et al., 2019) , which ignores inhomogeneous cytoplasmic background. We detected integrin α11 spots (pixel size 4) that colocalized with Lamp1 spots based on the distance between them (pixel distance 3). Then the percentage of integrin α11 spots that co-localized with Lamp1 spots was calculated as the number of colocalizing integrin α11 spots of the total number of integrin α11 spots.
